Hypertension, Pulmonary
Conditions
Keywords
Pulmonary Arterial Hypertension
Brief summary
To describe the prevalence, incidence and current treatment and procedures patterns in a US pediatric population with PAH in MarketScan database during the period 2010-2013
Interventions
DRUGAssigned pulmonary hypertension medication
As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* All PAH patients who were in the MarketScan database and who were under age 18 at some time during the years 2010 through 2013
Exclusion criteria
Not applicable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of PAH (pulmonary arterial hypertension) | Retrospective analysis of three year period |
| Prevalence rate of PAH | Retrospective analysis of three year period |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assigned drug treatment for PAH measured using the MarketScan database | Retrospective analysis of three year period | Description of pulmonary hypertension-targeted drugs prescribed in the study population and changes during the study period |
| Diagnostic procedures performed among PAH patients measured using the MarketScan database | Retrospective analysis of three year period | — |
| Prevalence of comorbidities among PAH patients | Retrospective analysis of three year period | — |
Countries
United States
Outcome results
None listed